Peter Hiatt
Overview
Explore the profile of Peter Hiatt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
408
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
De Boeck K, Munck A, Walker S, Faro A, Hiatt P, Gilmartin G, et al.
J Cyst Fibros
. 2014 Oct;
13(6):674-80.
PMID: 25266159
Background: Ivacaftor is used to treat patients with CF and a G551D gating mutation; the KONNECTION study assessed the efficacy and safety of ivacaftor in patients with CF and a...
2.
Kerby G, Rosenfeld M, Ren C, Mayer O, Brumback L, Castile R, et al.
Pediatr Pulmonol
. 2011 Nov;
47(6):597-605.
PMID: 22081559
Rationale: Conducting clinical trials in cystic fibrosis (CF) preschoolers has been limited by lack of sensitive lung function measures performed across sites. Objectives: (1) Assess feasibility and short-term reproducibility of...
3.
Treggiari M, Retsch-Bogart G, Mayer-Hamblett N, Khan U, Kulich M, Kronmal R, et al.
Arch Pediatr Adolesc Med
. 2011 Sep;
165(9):847-56.
PMID: 21893650
Objective: To investigate the efficacy and safety of 4 antipseudomonal treatments in children with cystic fibrosis with recently acquired Pseudomonas aeruginosa infection. Design: Randomized controlled trial. Setting: Multicenter trial in...
4.
Gibson R, Emerson J, Mayer-Hamblett N, Burns J, McNamara S, Accurso F, et al.
Pediatr Pulmonol
. 2007 May;
42(7):610-23.
PMID: 17534969
Rationale: Among young children with cystic fibrosis (CF), Pseudomonas aeruginosa (Pa) airway infection is associated with increased morbidity and mortality. Early intervention strategies include tobramycin solution for inhalation (TSI), which...
5.
Koumbourlis A, Chen X, Rao J, Schluchter M, Easley K, Colin A, et al.
Pediatr Pulmonol
. 2004 Mar;
37(4):318-23.
PMID: 15022128
We compared three methods of reporting maximal expiratory flow (V'maxFRC) measured in partial expiratory flow-volume curves (PEFVCs) at the point of functional residual capacity (FRC). PEFVCs were obtained with the...
6.
Ernst R, DArgenio D, Ichikawa J, Bangera M, Selgrade S, Burns J, et al.
Environ Microbiol
. 2003 Dec;
5(12):1341-9.
PMID: 14641578
Pseudomonas aeruginosa strains from the chronic lung infections of cystic fibrosis (CF) patients are phenotypically and genotypically diverse. Using strain PAO1 whole genome DNA microarrays, we assessed the genomic variation...
7.
Gibson R, Emerson J, McNamara S, Burns J, Rosenfeld M, Yunker A, et al.
Am J Respir Crit Care Med
. 2002 Dec;
167(6):841-9.
PMID: 12480612
We conducted a double-blind, placebo-controlled, multicenter, randomized trial to test the hypothesis that 300 mg of tobramycin solution for inhalation administered twice daily for 28 days would be safe and...